BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 13, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 15, 2018
View Archived Issues
Biopharma money raised: Jan. 1 - Oct. 11, 2018
Read More
Money raised by biopharma: 2018 vs. 2017
Read More
The week's biggest gainers and losers
Read More
BioWorld stock report for public biotechnology companies
Read More
Three quarters in, enthusiasm is high for biopharma deals in 2018, less so for M&As
Dealmaking for the biopharma industry has continued its steady climb through the third quarter of 2018, completing 18 percent more deals that in total are worth 25 percent more than they were this time last year.
Read More
Nothing GAINed: Antimicrobial companies see their shares tumble
According to FDA Commissioner Scott Gottlieb, “the emergence of antibiotic resistance threatens the advances we’ve made in medicine.”
Read More
Week in Washington
Read More
Phase II clinical trials: September 2018
Read More
Phase I clinical trials: September 2018
Read More
Phase III clinical trials: September 2018
Read More
Word on the street
Read More
